Q-omics provides the consensus-scored PRAMENP profile across patient tissues and cancer cell-line models. PRAMENP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRAMENP is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, PRAMENP RNA expression shows 8,209 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUAD, and TGCT as cancer lineages where PRAMENP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMENP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMENP survival associations across molecular data types. PRAMENP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMENP RNA expression–survival associations across cancer types. High PRAMENP expression shows unfavorable associations in KIRP, but favorable associations in HNSC, CESC, LUAD, LIHC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PRAMENP RNA expression.
This table summarizes PRAMENP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMENP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMENP shows lower tumor expression in READ, COAD, CHOL and KIRP and higher tumor expression in LUAD and KICH. The LUAD box plot shows higher PRAMENP RNA expression in tumor versus normal tissue (log2 FC = +0.324, t-test p < 0.001).
This table shows molecular features associated with PRAMENP in patient tissues and cancer cell lines. In patient samples, PRAMENP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
